Literature DB >> 34614283

Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.

Jaeki Min1, Anand Mayasundari1, Fatemeh Keramatnia1, Barbara Jonchere2, Seung Wook Yang3, Jamie Jarusiewicz1, Marisa Actis1, Sourav Das1, Brandon Young1, Jake Slavish1, Lei Yang1, Yong Li1, Xiang Fu1, Shalandus H Garrett1, Mi-Kyung Yun4, Zhenmei Li4, Stanley Nithianantham1, Sergio Chai1, Taosheng Chen1, Anang Shelat1, Richard E Lee1, Gisele Nishiguchi1, Stephen W White4, Martine F Roussel2, Patrick Ryan Potts3, Marcus Fischer1,4, Zoran Rankovic1.   

Abstract

Targeting cereblon (CRBN) is currently one of the most frequently reported proteolysis-targeting chimera (PROTAC) approaches, owing to favorable drug-like properties of CRBN ligands, immunomodulatory imide drugs (IMiDs). However, IMiDs are known to be inherently unstable, readily undergoing hydrolysis in body fluids. Here we show that IMiDs and IMiD-based PROTACs rapidly hydrolyze in commonly utilized cell media, which significantly affects their cell efficacy. We designed novel CRBN binders, phenyl glutarimide (PG) analogues, and showed that they retained affinity for CRBN with high ligand efficiency (LE >0.48) and displayed improved chemical stability. Our efforts led to the discovery of PG PROTAC 4 c (SJ995973), a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins that inhibited the viability of human acute myeloid leukemia MV4-11 cells at low picomolar concentrations (IC50 =3 pM; BRD4 DC50 =0.87 nM). These findings strongly support the utility of PG derivatives in the design of CRBN-directed PROTACs.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  IMiD; PG; PROTAC; cereblon; phenyl glutarimide

Mesh:

Substances:

Year:  2021        PMID: 34614283      PMCID: PMC8648984          DOI: 10.1002/anie.202108848

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  30 in total

Review 1.  Cereblon modulators: Low molecular weight inducers of protein degradation.

Authors:  Philip P Chamberlain; Brian E Cathers
Journal:  Drug Discov Today Technol       Date:  2019-03-13

Review 2.  Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.

Authors:  Scott D Edmondson; Bin Yang; Charlene Fallan
Journal:  Bioorg Med Chem Lett       Date:  2019-04-20       Impact factor: 2.823

3.  Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.

Authors:  Wenwei Lin; Yongtao Li; Jaeki Min; Jiuyu Liu; Lei Yang; Richard E Lee; Taosheng Chen
Journal:  Bioconjug Chem       Date:  2020-10-18       Impact factor: 4.774

4.  Targeted protein degradation: expanding the toolbox.

Authors:  Matthieu Schapira; Matthew F Calabrese; Alex N Bullock; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2019-10-30       Impact factor: 84.694

5.  The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species.

Authors:  H Schumacher; R L Smith; R T Williams
Journal:  Br J Pharmacol Chemother       Date:  1965-10

6.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Authors:  Jing Lu; Yimin Qian; Martha Altieri; Hanqing Dong; Jing Wang; Kanak Raina; John Hines; James D Winkler; Andrew P Crew; Kevin Coleman; Craig M Crews
Journal:  Chem Biol       Date:  2015-06-04

Review 7.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

8.  Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Authors:  Chong Qin; Yang Hu; Bing Zhou; Ester Fernandez-Salas; Chao-Yie Yang; Liu Liu; Donna McEachern; Sally Przybranowski; Mi Wang; Jeanne Stuckey; Jennifer Meagher; Longchuan Bai; Zhuo Chen; Mei Lin; Jiuling Yang; Danya N Ziazadeh; Fuming Xu; Jiantao Hu; Weiguo Xiang; Liyue Huang; Siwei Li; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2018-07-18       Impact factor: 7.446

9.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

10.  Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.

Authors:  Gisele Nishiguchi; Fatemeh Keramatnia; Jaeki Min; Yunchao Chang; Barbara Jonchere; Sourav Das; Marisa Actis; Jeanine Price; Divyabharathi Chepyala; Brandon Young; Kevin McGowan; P Jake Slavish; Anand Mayasundari; Jamie A Jarusiewicz; Lei Yang; Yong Li; Xiang Fu; Shalandus H Garrett; James B Papizan; Kiran Kodali; Junmin Peng; Shondra M Pruett Miller; Martine F Roussel; Charles Mullighan; Marcus Fischer; Zoran Rankovic
Journal:  J Med Chem       Date:  2021-05-27       Impact factor: 7.446

View more
  4 in total

1.  Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.

Authors:  Lisa J Alcock; Yunchao Chang; Jamie A Jarusiewicz; Marisa Actis; Stanley Nithianantham; Anand Mayasundari; Jaeki Min; Dylan Maxwell; Jeremy Hunt; Brandon Smart; Jun J Yang; Gisele Nishiguchi; Marcus Fischer; Charles G Mullighan; Zoran Rankovic
Journal:  ACS Med Chem Lett       Date:  2022-02-21       Impact factor: 4.345

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  PROTACs for BRDs proteins in cancer therapy: a review.

Authors:  Chao Wang; Yujing Zhang; Shanbo Yang; Wujun Chen; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 4.  Discovery of E3 Ligase Ligands for Target Protein Degradation.

Authors:  Jaeseok Lee; Youngjun Lee; Young Mee Jung; Ju Hyun Park; Hyuk Sang Yoo; Jongmin Park
Journal:  Molecules       Date:  2022-10-02       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.